STOCK TITAN

Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

Telo Genomics (OTCQB: TDSGF) presented a groundbreaking poster abstract on minimal residual disease (MRD) at the 22nd International Myeloma Society Annual Meeting in Toronto. The presentation introduced a novel workflow combining Multiple Myeloma (MM) Circulating Tumor Cells (CTCs) enumeration with TeloView® 3D telomere profiling platform.

The innovative methodology offers a less invasive biomarker for Multiple Myeloma by analyzing peripheral blood instead of bone marrow. This approach provides functional and biologically actionable data beyond traditional enumeration methods, helping assess disease progression risk. The abstract will be published in the Clinical Lymphoma, Myeloma, & Leukemia Journal.

Telo Genomics (OTCQB: TDSGF) ha presentato un abstract poster innovativo sulla malattia residua minima (MRD) durante la 22ª Riunione annuale della International Myeloma Society a Toronto. La presentazione ha introdotto un flusso di lavoro innovativo che combina il conteggio delle Cellule Tumorali Circolanti del Mieloma Multiplo (CTCs/MM) con la piattaforma di profilazione 3D dei telomeri TeloView®.

La metodologia innovativa offre un biomarker meno invasivo per il mieloma multiplo analizzando il sangue periferico anziché il midollo osseo. Questo approccio fornisce dati funzionali e biologicamente azionabili oltre i metodi di enumerazione tradizionali, aiutando a valutare il rischio di progressione della malattia. L’abstract sarà pubblicato sulla rivista Clinical Lymphoma, Myeloma, & Leukemia.

Telo Genomics (OTCQB: TDSGF) presentó un abstract poster revolucionario sobre enfermedad residual mínima (MRD) en la 22ª Reunión Anual de la International Myeloma Society en Toronto. La presentación introdujo un flujo de trabajo novedoso que combina la enumeración de Células Tumorales Circulares (CTCs) del MM con la plataforma de perfil 3D de telómeros TeloView®.

La metodología innovadora ofrece un biomarcador menos invasivo para el Mieloma Múltiple al analizar la sangre periférica en lugar de la médula ósea. Este enfoque proporciona datos funcionales y biológicamente accionables más allá de los métodos tradicionales de enumeración, ayudando a evaluar el riesgo de progresión de la enfermedad. El resumen será publicado en la revista Clinical Lymphoma, Myeloma, & Leukemia.

Telo Genomics (OTCQB: TDSGF) 토론토에서 열린 제22차 국제 다발성 골수종 학회 연차대회에서 최소 잔류 질환(MRD)에 관한 혁신적인 포스터 초록을 발표했다. 이 발표는 다발성 골수종(MM) 순환 종양세포(CTCs)의 수를 세는 방법과 TeloView® 3D 텔로미어 프로파일링 플랫폼을 결합하는 새로운 워크플로를 소개했다.

이 혁신적 방법은 골수 대신 말초혈액을 분석함으로써 다발성 골수종에 대한 덜 침습적인 바이오마커를 제공한다. 이 접근법은 전통적인 수치화 방법을 넘어 기능적이고 생물학적으로 실행 가능한 데이터를 제공하여 질병 진행 위험을 평가하는 데 도움을 준다. 초록은 Clinical Lymphoma, Myeloma, & Leukemia 저널에 게재될 예정이다.

Telo Genomics (OTCQB: TDSGF) a présenté un poster-abstract révolutionnaire sur la maladie résiduelle minimale (MRD) lors de la 22e Réunion annuelle de la International Myeloma Society à Toronto. La présentation a introduit un flux de travail novateur combinant l’énumération des cellules tumorales circulantes du myélome multiple (MM-CTCs) avec la plateforme de profiling télomérique 3D TeloView®.

La méthodologie innovante offre un biomarqueur moins invasif pour le myélome multiple en analysant le sang périphérique plutôt que la moelle osseuse. Cette approche fournit des données fonctionnelles et biologiquement exploitables au-delà des méthodes d’énumération traditionnelles, aidant à évaluer le risque de progression de la maladie. Le résumé sera publié dans le Clinical Lymphoma, Myeloma, & Leukemia Journal.

Telo Genomics (OTCQB: TDSGF) präsentierte ein bahnbrechendes Poster-Abstract zur minimalen Resterkrankung (MRD) auf dem 22. International Myeloma Society Annual Meeting in Toronto. Die Präsentation führte einen neuartigen Workflow ein, der Multiples Myelom (MM) zirkulierende Tumorzellen (CTCs) Enumeration mit der TeloView® 3D Telomer-Profiling-Plattform kombiniert.

Die innovative Methodik bietet einen weniger invasiven Biomarker für das Multiples Myelom, indem sie statt des Knochenmarks das periphere Blut analysiert. Dieser Ansatz liefert funktionale und biologisch umsetzbare Daten jenseits herkömmlicher Enumerationsmethoden und hilft, das Risiko des Krankheitsfortschreitens zu bewerten. Der Abstract wird in der Clinical Lymphoma, Myeloma, & Leukemia Journal veröffentlicht.

تيولو جينوميكس (OTCQB: TDSGF) قدمت ملخص بوستر رائد عن المرض المتبقّي المصغر (MRD) في الاجتماع السنوي الحادي والعشرين للجمعية الدولية للورم النخاعي في تورنتو. قدم العرض إطار عمل جديد يجمع خلايا ورمية دموية محمولة للورم المتعدد (MM CTCs) مع منصة TeloView® لتProfiling التيلوميرات ثلاثية الأبعاد.

تقدم المنهجية المبتكرة مؤشراً حيوياً أقل توغلاً للورم المتعدد عن طريق تحليل الدم المحيطي بدلاً من نخاع العظم. يوفر هذا النهج بيانات وظيفية وبايولوجية قابلة للتطبيق تتجاوز أساليب العد التقليدية، مما يساعد في تقييم مخاطر تقدم المرض. سيتم نشر الملخص في مجلة Clinical Lymphoma, Myeloma, & Leukemia.

Telo Genomics (OTCQB: TDSGF) 在多发性骨髓瘤协会(International Myeloma Society)第22届年会在多伦多召开时,公布了一份关于最小残留病变(MRD)的突破性海报摘要。该演讲介绍了一种新颖的工作流程,将多发性骨髓瘤(MM)循环肿瘤细胞(CTCs)计数与 TeloView® 3D 端粒分析平台相结合。

这种创新方法通过分析外周血而非骨髓,提供一种侵入性更低的生物标志物,从而获得超越传统计数方法的功能性和生物学可操作数据,帮助评估疾病进展风险。摘要将刊载于 Clinical Lymphoma, Myeloma, & Leukemia 杂志。

Positive
  • None.
Negative
  • None.

Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company has presented a poster abstract on minimal residual disease ("MRD") during the 22nd International Myeloma Society Annual Meeting in Toronto, Canada.

The abstract, titled "3D Telomere Profiling of MRD in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression", was presented at the meeting by Dr. Yulia Shifrin, Laboratory Director of Telo Genomics. The abstract will be published as a special supplement to the Clinical Lymphoma, Myeloma, & Leukemia Journal and made available on the Company website.

The poster presentation describes a new workflow for MRD evaluation that combines the enumeration and immunophenotyping of individual Multiple Myeloma (MM) Circulating Tumor Cells (CTCs), with the TeloView® 3D telomere profiling platform. The evaluation of CTCs from peripheral blood, rather than bone marrow, offers a less invasive biomarker for MM that allows for continuous monitoring of patients. Unlike conventional approaches, this approach yields functional and biologically actionable data on disease cells, providing insights on risk of disease progression beyond simple enumeration.

The International Myeloma Society (IMS) is a global professional organization dedicated to advancing the science and treatment of multiple myeloma. Its 22nd Annual Meeting is taking place from September 17-20, 2025. IMS meetings are widely considered as a defining annual forum in the myeloma field.

About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.

About MRD Assessment
MRD is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells as in remission or active provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals. Minimal residual disease (MRD) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is expected to reach USD 4.1 billion by 2032 (Globe Newswire - August 14, 2023).

About Multiple Myeloma
Multiple Myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receive treatment at any given time. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US.

For further information, please contact:
Brett Maas
Managing Partner
(646) 536-7331
Brett@HaydenIR.com
7320 E. Butherus Drive
Scottsdale, AZ 85260
haydenir.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267087

FAQ

What new technology did Telo Genomics (TDSGF) present at the 2025 IMS Meeting?

Telo Genomics presented a new MRD workflow that combines Multiple Myeloma Circulating Tumor Cells enumeration with TeloView® 3D telomere profiling platform, offering less invasive monitoring through peripheral blood analysis.

How does Telo Genomics' new MRD methodology differ from conventional approaches?

Unlike conventional approaches, it analyzes peripheral blood instead of bone marrow, providing less invasive monitoring and delivers functional and biologically actionable data on disease cells beyond simple enumeration.

When and where was Telo Genomics' MRD research presented?

The research was presented at the 22nd International Myeloma Society Annual Meeting in Toronto, Canada, taking place from September 17-20, 2025.

Where will Telo Genomics' MRD research be published?

The abstract will be published as a special supplement to the Clinical Lymphoma, Myeloma, & Leukemia Journal and will be available on the Company's website.
Telo Genomics

OTC:TDSGF

TDSGF Rankings

TDSGF Latest News

TDSGF Stock Data

5.52M
96.38M
3.89%
0.34%
Diagnostics & Research
Healthcare
Link
Canada
Toronto